Ravi Jagatia, Ewald J Doornebal, Una Rastovic, Nicola Harris, Moyosoreoluwa Feyide, Anabel Martinez Lyons, Rosa Miquel, Yoh Zen, Ane Zamalloa, Farooq Malik, Andreas Prachalias, Krishna Menon, Luke Boulter, Simon Eaton, Nigel Heaton, Sandra Phillips, Shilpa Chokshi, Elena Palma
BACKGROUND: The exploitation of anti-tumour immunity, harnessed through immunomodulatory therapies, has fundamentally changed the treatment of primary liver cancer (PLC). However, this has posed significant challenges in preclinical research. Novel immunologically relevant models for PLC are urgently required to improve the translation from bench to bedside and back, explore and predict effective combinatorial therapies, aid novel drug discovery and develop personalised treatment modalities...
October 6, 2023: EBioMedicine